Zelira Therapeutics Ltd (STU:G1G)
€ 0.352 0.024 (7.32%) Market Cap: 4.12 Mil Enterprise Value: 7.37 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 5/100

Zelira Therapeutics Ltd Investor Webinar Transcript

May 31, 2023 / 02:00AM GMT
Ronn Bechler
Automic Group - Executive Director

Good afternoon, everybody, and good evening in the US. Thank you very much for joining us today for this group webinar by Zelira Therapeutics. We have Chairman Osagie Imasogie and Global CEO Oludare Odumosu presenting to us today off the back of the announcement this morning, which many of you will have seen, regarding the results that have come out in relation to Zelira's diabetic nerve pain drug outperforming a big pharma drug.

I don't want to take all the limelight away from the two of you, because I know you're very excited. So I'll hand across to you, Osagie, to do a brief intro, and then Dare can take us through the slides. (Operator Instructions). So Osagie, I'll hand over to you. Thank you.

Osagie Imasogie
Zelira Therapeutics Limited - Chairman

Thank you very much, Ronn. I appreciate that. Good morning for those in Australia, and good evening for those of our shareholders in the US. As Ronn said, we're quite pleased to have this dialogue after the results we just announced. You know, the normal

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot